Surrozen, Inc.

SRZN Healthcare Biotechnology

Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

23.44 1.63 −6.50%
Market cap
$294.7M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
n/a
Altman Z
−7.50
Beneish M
−14.31
Dividend safety
n/a
Dec '17 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — — 0.00 — 0.00 0.00
P/S ratio
— — — 0.00 — 0.00 48.61
Altman Z-Score
— — — (2.43) — (8.61) (7.50)
P/FCF ratio
— — — 0.00 — 0.00 0.00
Altman Z″-Score (non-manufacturers)
— — — 1.35 — (18.77) (15.54)
P/Operating CF
— — — (95.04) — 12.09 (29.08)
Beneish M-Score
— — — — — — (14.31)
P/B ratio
— — — 0.26 — 0.00 0.00
Price to Tangible BV
— — — 0.26 — 0.00 0.00
EV/Sales
— — — 0.00 — 0.00 22.94
EV/EBITDA
— — — 1.03 — 0.00 0.00
EV/Operating CF
— — — 1.28 — (0.43) (2.64)
EV/FCF
— — — 1.26 — (0.43) (2.63)
Quick Ratio
— 6.76 7.50 8.00 5.34 5.07 9.01
Current Ratio
— 6.90 7.75 8.35 5.75 5.32 9.22
Net Debt/EBITDA
— 1.59 1.95 1.79 0.81 1.43 2.15
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.11 0.00 0.23 0.05
Operating CF/Net income
— 0.89 0.89 1.23 0.94 0.28 0.13
Capex/Depreciation
— (0.45) (0.58) (0.35) (0.34) (0.02) (0.24)
ROE
— (32.72%) (69.62%) (38.78%) (75.55%) (767.91%) 231.45%
ROA
— (105.43%) (54.86%) (31.78%) (63.52%) (134.46%) (328.86%)
ROIC
— 0.00% (433.10%) (17,001.15%) (1,512.29%) 0.00% 0.00%
Return on Tangible Assets
— (67.07%) (56.68%) (47.88%) (119.72%) (197.53%) (294.93%)
Average Days of Receivables
— — — 57.76 0.00 87.05 21.83
Research and Development Expense of Revenue
— 0.00% 0.00% 296.10% 0.00% 198.33% 844.55%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 158.61% 0.00% 141.36% 466.03%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% 0.00% 36.14% 0.00% 38.61% 110.30%
Graham Net Nets
— — — 3.48 — (0.73) (1.15)
Graham Number
— — — 0.00 — 59.75 137.30
Earnings Yield
— — — (185.18%) — (151.71%) (147.65%)
Free Cash Flow Yield
— — — (230.31%) — (41.94%) (17.97%)
Revenue per Share
— 0.00 0.00 5.40 0.00 3.63 0.47
Operating CF per Share
— (27.31) (29.64) (19.08) (20.00) (6.01) (4.04)
Capex per Share
— (0.82) (0.77) (0.31) (0.20) (0.01) (0.02)
Free Cash Flow per Share
— (28.13) (30.41) (19.39) (20.20) (6.02) (4.06)
Cash per Share
— 46.16 61.85 32.77 17.86 11.78 11.93
Shareholders Equity per Share
— 44.39 66.61 32.84 18.80 (7.29) (25.11)
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 44.39 66.61 32.84 18.80 (7.29) (25.11)
Free Cash Flow
— (29.97) (50.08) (44.87) (40.76) (17.65) (30.37)
Working Capital
— 42.95 91.62 71.57 33.98 31.62 81.63
Capital Expenditures
— (0.87) (1.27) (0.73) (0.40) (0.03) (0.13)
Net Current Asset Value
— 35.46 77.72 67.87 32.99 (30.91) (194.93)
EV/EBIT
— — — 1.27 — 0.00 0.00
Capex to Sales
— 0.00 0.00 0.06 0.00 0.00 0.04
Price to Operating Income
— — — 0.00 — 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.33 0.45 0.57 0.60 2.57 1.24
Cash ROIC
— (31.07%) (23.67%) (29.55%) (55.10%) (133.89%) 30.83%
Accounts Receivable Turnover
— — — 0.00 0.00 4.54 2.53
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 — — —
Average Receivables
— — — — 2.07 2.35 1.37
Average Payables
— 2.25 2.25 1.69 0.59 0.42 0.52
Average Assets
— 31.03 99.62 113.30 67.76 47.27 73.60
Average Common Equity
— 99.98 78.50 92.85 56.97 8.28 (104.57)

Fold the line items

Columns are period end dates